Antiangiogenic agents, such as ramucirumab, should be cautiously administered along with radiotherapy because of the enhanced risk of adverse events.
Keywords: antiangiogenic agent; bone metastasis; esophageal stenosis; palliative radiotherapy; ramucirumab.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.